VuCOMP receives FDA approval for M-Vu CAD for mammography version 3.1 -
VuCOMP, Inc., a leader in the development of advanced systems of computer vision for breast cancer detection, today announced it has received US Food and Drug administration (FDA) for M-Vu CAD for version 3.1 of mammography. Meanwhile, VuCOMP published an update of its CAD station that includes the ability to process additional views of standard screening. Overall, the CAD system updates provide radiologists with faster processing, improved workflow and better parallel architecture.
Jim Pike, President and CTO of VuCOMP said: "We are committed to continuous improvement of our product range, and each new version of M-Vu CAD provides advanced that bring substantial value system and to our customers. These updates are no exception. "
M-Vu CAD system uses advanced algorithms computer vision to identify areas of mammograms that are compatible with breast cancer. M-Vu CAD Version 1 was the first product to meet the standard of player FDA recommended study to prove the effectiveness of CAD. VuCOMP mammography continues to provide updates of systematic products respect the commitment of the company to ongoing improvements to its customers, without additional costs.
M-Vu CAD is approved for digital mammography systems manufactured by Carestream, Fuji, GE, Giotto, Hologic, Konica Minolta, Philips, Planmed and Siemens. for clinical having a variety of systems digital mammography, M-Vu can now provide a unified solution.
in addition to M-Vu CAD, VuCOMP has developed and commercialized M-Vu breast density which received FDA marketing authorization in December 2013 . both products have been adopted by leading radiologists and are used in clinics around the world. The company has other products in the development pipeline.
EmoticonEmoticon